Y Intercept Hong Kong Ltd Increases Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Y Intercept Hong Kong Ltd increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 22.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 11,525 shares of the biopharmaceutical company’s stock after acquiring an additional 2,100 shares during the quarter. Regeneron Pharmaceuticals makes up approximately 0.5% of Y Intercept Hong Kong Ltd’s holdings, making the stock its 12th biggest holding. Y Intercept Hong Kong Ltd’s holdings in Regeneron Pharmaceuticals were worth $8,210,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of REGN. State Street Corp grew its position in shares of Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after purchasing an additional 61,277 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock worth $707,759,000 after buying an additional 11,499 shares during the last quarter. Swiss National Bank grew its holdings in Regeneron Pharmaceuticals by 0.6% in the 3rd quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock valued at $338,079,000 after buying an additional 2,000 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Regeneron Pharmaceuticals by 0.4% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 302,616 shares of the biopharmaceutical company’s stock valued at $215,562,000 after acquiring an additional 1,108 shares during the last quarter. Finally, National Pension Service lifted its holdings in shares of Regeneron Pharmaceuticals by 17.0% during the 3rd quarter. National Pension Service now owns 223,617 shares of the biopharmaceutical company’s stock worth $235,075,000 after acquiring an additional 32,457 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on REGN. Barclays lowered their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Canaccord Genuity Group started coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. Truist Financial cut their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Wolfe Research began coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target for the company. Finally, BMO Capital Markets dropped their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research note on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $700.33 on Monday. The stock has a market cap of $76.56 billion, a P/E ratio of 18.29, a price-to-earnings-growth ratio of 2.34 and a beta of 0.08. The stock has a 50 day moving average of $699.40 and a 200-day moving average of $881.17. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $11.86 EPS. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.50%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.